PURPOSE OF REVIEW: Pulmonary hypertension is a common complication seen in patients with advanced chronic obstructive pulmonary disease (COPD). Information related to the true prevalence, implications for functional outcomes, pathogenesis, and therapeutic options available has been lacking. The purpose of this review is to summarize some exciting findings from the last several years that address these holes in our knowledge. RECENT FINDINGS: Several recent studies have explored the prevalence and the functional implications of pulmonary hypertension for patients with COPD. These highlight the importance of clearly defining pulmonary hypertension that can be quite heterogeneous in this patient population. Furthermore, the concept that pulmonary hypertension in COPD is merely driven by hypoxic vasoconstriction has been called into question by several lines of investigation that suggest a much more complex pathogenesis potentially occurring independently of hypoxemia. Finally, there has been much interest in exploring pulmonary hypertension-specific therapies in patients with COPD, but available data to support their use are limited. SUMMARY: The recent findings summarized here have expanded our knowledge regarding this important comorbidity in patients with advanced COPD. We now know that pulmonary hypertension is common, has clear effects on both morbidity and mortality, and has a complex pathophysiology that we are only beginning to understand.
PURPOSE OF REVIEW: Pulmonary hypertension is a common complication seen in patients with advanced chronic obstructive pulmonary disease (COPD). Information related to the true prevalence, implications for functional outcomes, pathogenesis, and therapeutic options available has been lacking. The purpose of this review is to summarize some exciting findings from the last several years that address these holes in our knowledge. RECENT FINDINGS: Several recent studies have explored the prevalence and the functional implications of pulmonary hypertension for patients with COPD. These highlight the importance of clearly defining pulmonary hypertension that can be quite heterogeneous in this patient population. Furthermore, the concept that pulmonary hypertension in COPD is merely driven by hypoxic vasoconstriction has been called into question by several lines of investigation that suggest a much more complex pathogenesis potentially occurring independently of hypoxemia. Finally, there has been much interest in exploring pulmonary hypertension-specific therapies in patients with COPD, but available data to support their use are limited. SUMMARY: The recent findings summarized here have expanded our knowledge regarding this important comorbidity in patients with advanced COPD. We now know that pulmonary hypertension is common, has clear effects on both morbidity and mortality, and has a complex pathophysiology that we are only beginning to understand.
Authors: Harry Karmouty-Quintana; Tingting Weng; Luis J Garcia-Morales; Ning-Yuan Chen; Mesias Pedroza; Hongyan Zhong; Jose G Molina; Raquel Bunge; Brian A Bruckner; Yang Xia; Richard A Johnston; Matthias Loebe; Dewan Zeng; Harish Seethamraju; Luiz Belardinelli; Michael R Blackburn Journal: Am J Respir Cell Mol Biol Date: 2013-12 Impact factor: 6.914
Authors: Adelheid Kratzer; Jonas Salys; Claudia Nold-Petry; Carlyne Cool; Martin Zamora; Russ Bowler; Andreas Rembert Koczulla; Sabina Janciauskiene; Michael G Edwards; Charles A Dinarello; Laimute Taraseviciene-Stewart Journal: Am J Respir Cell Mol Biol Date: 2013-06 Impact factor: 6.914
Authors: Mark Bryant; Sebastian Ley; Ralf Eberhardt; Ravi Menezes; Felix Herth; Oliver Sedlaczek; Hans-Ulrich Kauczor; Julia Ley-Zaporozhan Journal: Eur Radiol Date: 2014-08-28 Impact factor: 5.315
Authors: Kristi M Porter; Bum-Yong Kang; Sherry E Adesina; Tamara C Murphy; C Michael Hart; Roy L Sutliff Journal: PLoS One Date: 2014-06-06 Impact factor: 3.240